Multiply Labs, a San Francisco-based company building robotic manufacturing systems for cell and gene therapies, announced a $75 million Series B financing on October 11, 2026. The round was led by Dr. Patrick Soon-Shiong and NantWorks, with new investors AstraZeneca, Lingotto, Teradyne, and Strange Ventures joining returning backers Casdin Capital, Lux Capital, Fifty Years, and Founders Fund.
The raise is one of the largest recent financings in pharmaceutical manufacturing technology, and it carries a signal that investors should not miss: both a global pharma giant and a robotics-automation leader now sit on the same cap table. That pairing reflects where biomanufacturing is heading — toward flexible, robot-driven factories that can produce complex cell therapies at a fraction of today's cost.
What Multiply Labs actually does
Cell and gene therapies represent a genuine medical revolution — one-time treatments that can cure certain cancers and genetic disorders. But making them is brutally difficult. Unlike a traditional pill, a CAR-T cell therapy is manufactured from a patient's own cells through a multi-step biological process that has historically been done largely by hand in expensive cleanroom facilities. The result: treatments that cost hundreds of thousands of dollars per dose, with manufacturing capacity as the hard bottleneck on patient access.
Multiply Labs builds robotic systems that automate the production of cell therapies. Instead of human technicians performing delicate cell-culture steps inside cleanrooms, Multiply's robots handle the fluid handling, incubation, and quality control — running 24/7 with the consistency that biology demands. The thesis is straightforward: automation drives down cost per dose, increases throughput, and reduces the batch-to-batch variability that plagues manual processes.
Why this investor mix matters
Funding rounds are often judged by headline size, but the composition of a syndicate tells the deeper story. This round assembles three distinct types of strategic capital:
Dr. Patrick Soon-Shiong and NantWorks. Soon-Shiong is a surgeon, inventor, and biotech entrepreneur who built and sold Abraxis BioScience (maker of the cancer drug Abraxane) to Celgene for $2.9 billion in 2010, and later founded NantWorks, a healthcare technology ecosystem spanning cancer care, immunotherapy, and health data. His leadership of the round is a vote of confidence from someone who has personally scaled biotech manufacturing.
AstraZeneca. One of the world's largest pharmaceutical companies, AstraZeneca has been aggressively building its cell-therapy capabilities, including its acquisition of the CAR-T company Neogene and its Cambridge manufacturing investments. A strategic investment from AstraZeneca suggests a pharma buyer is thinking about its future supply chain — robotic manufacturing could be how cell therapies move from boutique hospital-adjacent facilities to true industrial scale.
Teradyne. Known for semiconductor test equipment and industrial robotics (through its Universal Robots and Mobile Industrial Robots divisions), Teradyne brings deep expertise in precision automation. Its participation signals that the robotics industry sees biomanufacturing as a genuine growth frontier for automation technology, not just a niche.
Lingotto — the investment company associated with the Agnelli family's Exor — and Strange Ventures round out the new money, while the return of Casdin, Lux, Fifty Years, and Founders Fund shows existing conviction from specialist biotech and deep-tech investors.
Why it matters for founders and investors
The cell-therapy industry's central problem is no longer clinical efficacy — it is manufacturability. Dozens of promising therapies are stuck in a gap between regulatory approval and commercial viability because nobody can make them cheaply enough or at sufficient volume. That makes manufacturing technology a picks-and-shovels play on the entire cell-therapy sector: if you own the robotic factory, you participate in every therapy that runs through it.
For founders, the Multiply Labs round illustrates a powerful fundraising pattern: assemble a syndicate where strategic investors each bring something different — the domain visionary (Soon-Shiong), the future customer (AstraZeneca), the technology enabler (Teradyne) — and let their co-presence validate the thesis to everyone else. Investors in 2026 are rewarding companies whose cap tables read like an industry coalition.
For investors, robotic biomanufacturing sits at the intersection of two long-duration tailwinds: the cell-therapy pipeline, which keeps expanding as new indications are approved, and industrial automation, which keeps getting cheaper and more capable. The $75 million Series B suggests this intersection is moving from thesis to commercial reality.
Angeled.com connects founders with investors.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



